Summary
EudraCT Number: 2009-014391-22
Sponsor's Protocol Code Number: CCBC134A2404
National Competent Authority: Spain - AEMPS 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2009-12-30
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014391-22/ES/

A. Protocol Information
A.1 Member State Concerned: Spain - AEMPS
A.2 EudraCT number: 2009-014391-22
A.3 Full title of the trial: Estudio fase IIIb comparativo, abierto, multicéntrico y aleatorizado para evaluar la eficacia y la seguridad de daptomicina intravenosa (i.v.) en comparación con penicilinas semisintéticas (PSS) o vancomicina en el tratamiento de pacientes ancianos >ó =65 años de edad) con infecciones complicadas de piel y tejidos blandos (IPTBc)

An open label, multi-center, randomized, comparative Phase IIIb study to compare efficacy and safety of intravenous (i.v.) daptomycin with that of Semi-synthetic Penicillins (SSPs) or vancomycin in the treatment of elderly patients (aged > or = 65 years) with complicated Skin and Soft Tissue Infections (cSSTIs)
A.4.1 Sponsor's protocol code number: CCBC134A2404
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: Novartis Farmacéutica S.A.
B.1.3.4	Country: Spain
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: CUBICIN 350 mg polvo para concentrado para solución para perfusión
D.2.1.1.2 Name of the Marketing Authorisation holder: NOVARTIS EUROPHARM LTD.
D.2.1.2 Country which granted the Marketing Authorisation: Spain
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Powder for solution for injection
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: DAPTOMICINA
D.3.9.1 CAS number: 103060-53-3
D.3.9.2 Current sponsor code: CBC134
D.3.9.3 Other descriptive name: DAPTOMICINA
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 350 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: Yes
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 2
D.1.2 and D.1.3 IMP Role: Comparator
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Information not present in EudraCT
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: vancomicina
D.3.4 Pharmaceutical form: Powder for solution for injection
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: VANCOMICINA
D.3.9.1 CAS number: 1404906
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 500 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 3
D.1.2 and D.1.3 IMP Role: Comparator
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Information not present in EudraCT
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Cloxacilina
D.3.4 Pharmaceutical form: Powder and solvent for solution for injection
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: CLOXACILINA
D.3.9.1 CAS number: 61723
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 500 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 4
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: CUBICIN 500 mg polvo para concentrado para solución para perfusión
D.2.1.1.2 Name of the Marketing Authorisation holder: NOVARTIS EUROPHARM LTD.
D.2.1.2 Country which granted the Marketing Authorisation: Spain
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Powder for solution for infusion
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: DAPTOMICINA
D.3.9.1 CAS number: 103060-53-3
D.3.9.3 Other descriptive name: DAPTOMICINA
D.3.10 Strength
D.3.10.1 Concentration unit: mg/g milligram(s)/gram
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 500 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: Yes
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 5
D.1.2 and D.1.3 IMP Role: Comparator
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Information not present in EudraCT
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: vancomicina
D.3.4 Pharmaceutical form: Powder for solution for injection
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: VANCOMICINA
D.3.9.1 CAS number: 1404906
D.3.10 Strength
D.3.10.1 Concentration unit: g gram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 1 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 6
D.1.2 and D.1.3 IMP Role: Comparator
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Information not present in EudraCT
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Cloxacilina
D.3.4 Pharmaceutical form: Powder and solvent for solution for injection
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: CLOXACILINA
D.3.9.1 CAS number: 61723
D.3.10 Strength
D.3.10.1 Concentration unit: g gram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 1 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Infecciones complicadas de piel y tejidos blandos 
Complicated skin and soft tissue infections.
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 9
E.1.2 Level: HLGT
E.1.2 Classification code: 10040792
E.1.2 Term: Skin and subcutaneous tissue infections and infestations
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: Evaluar y comparar de forma descriptiva el éxito clínico en la visita de comprobación de la curación (CDC) en pacientes ancianos >ó =65 años de edad) con IPTBc tratados con 4 ó 6 mg/kg de daptomicina i.v.una vez al día comparado con los antibióticos comparadores
E.2.2 Secondary objectives of the trial: Hacer una evaluación descriptiva del resultado microbiológico de daptomicina en comparación con el obtenido con los antibióticos comparadores en el tratamiento de las IPTBc, medido por la proporción de pacientes que en la visita de CDC presenten erradicación bacteriológica de los microorganismos patógenos grampositivos basales.
Evaluar la duración del tratamiento (i.v., i.v. + oral). 
Evaluar las frecuencias de acontecimientos adversos y de anomalías analíticas observadas en pacientes ancianos tratados con 4 y 6 mg/kg una vez al día de daptomicina intravenosa y hacer una comparación descriptiva con las observadas con los antibióticos comparadores (evaluación de la seguridad)
E.2.3 Trial contains a sub-study: No
E.3 Principal inclusion criteria: Los pacientes elegibles para la inclusión en este estudio deberán cumplir todas los criterios:
1.Consentimiento informado por escrito para participar en el estudio. Si un paciente no puede otorgar su consentimiento, podrá hacerlo su representante legal por los medios aprobados por el CE del investigador.
2.El paciente tiene  65 años de edad o más.
3.Infección de gravedad suficiente como para requerir la hospitalización del paciente y la administración de tratamiento antimicrobiano por vía parenteral durante 96 horas como mínimo.
4.Pacientes con diagnóstico de infección complicada de piel y tejidos blandos (IPTBc) por bacterias grampositivas, con o sin bacteriemia, p.e:
-Infecciones de heridas debidas a:
lesión traumática (por ejemplo, aplastamiento, punción, laceración, disparo, etc.),
incisión quirúrgica,
cuerpo extraño (por ejemplo, flebitis séptica asociada al punto de inserción de un catéter intravenoso). Los cuerpos extraños infectados (por ejemplo, marcapasos implantados) se extraerán en las 24 horas siguientes a la inclusión en el estudio.
-Abscesos importantes; son aquellos que cumplen las siguientes condiciones:
afectan a los tejidos subcutáneos o a tejidos más profundos
precisan incisión y drenaje quirúrgicos,
precisan tratamiento antibiótico, además del drenaje.
-Ántrax intenso
-Ulceras infectadas (salvo pacientes con múltiples úlceras infectadas, véanse los criterios de exclusión) asociadas a: diabetes, insuficiencia vascular, presión (es decir, úlceras de decúbito),
-Presencia de una complicación, como:
lesión cutánea o trastorno subyacente previos que afecten de modo adverso a la administración del fármaco en la zona afectada, a la respuesta inmunitaria o la cicatrización del tejido,
necesidad de intervención quirúrgica importante,
sospecha o confirmación de afectación de tejidos blandos profundos, fascia o músculo,
esteroides sistémicos crónicos (> 20 mg de prednisona al día o equivalente),
diabetes mellitus que requiera tratamiento con antidiabéticos orales o con insulina.
5.Presencia de al menos 3 de los siguientes signos y síntomas de infección cutánea:
temperatura >38,0 °C en el recto o > 37,5 °C en boca/tímpano,
elevación de la cifra de leucocitos >12 x 103/microlitros; o con > 10 % de cayados (neutrófilos inmaduros),
drenaje y/o supuración del foco de infección,
eritema (que se extiende al menos 1 cm más allá del borde de la herida),
fluctuación,
calor y/o sensación localizada de aumento de la temperatura,
dolor y/o hipersensibilidad a la palpación,
edema y/o induración.
E.4 Principal exclusion criteria: Los pacientes que cumplan cualquiera de los criterios siguientes no podran participar:
IPTB no complicada
1.Afecciones que precisan cirugía que por sí sola curaría la infección o eliminaría la zona infectada (p.e, amputación)
2.Infecciones cutáneas leves o superficiales (p.e. forúnculos, abscesos sencillos, acné, impétigo).
3.Celulitis, incluida la erisipela, no asociada a complicaciones. Podrán participar los pacientes con celulitis asociada a una infección más grave (p.e., herida quirúrgica, úlcera diabética, infección de tejidos profundos), pero el porcentaje de estos pacientes se limitará al 30 %.
Infecciones cuyo desenlace sea difícil de evaluar:
4.Absceso perirrectal.
5.Hidradenitis supurativa.
6.Gangrena.
7.Mordeduras o picaduras infectadas, producidas por seres humanos o por animales.
8.Varias úlceras infectadas en lugares distantes entre sí.
9.Quemaduras infectadas (sólo quemaduras de tercer grado o quemaduras de más de 10 cm de diámetro).
10.Afecciones que precisen cirugía de urgencia, como la fascitis necrosante.
Trastornos médicos:
11.Antecedentes de alergia o intolerancia significativa a la vancomicina o la daptomicina. La hipersensibilidad a las PSS no es un criterio de exclusión.
12.Sospecha o confirmación clínica de trastorno o infección concomitante en otro foco al entrar en el estudio, que pueda interferir en la evaluación de este protocolo, como trastornos musculares primarios, neumonía, endocarditis, osteomielitis, artritis séptica, meningitis, absceso epidural raquídeo, infección intrabdominal (peritonitis, etc.) y bacteriemia intravascular relacionada con algún producto sanitario.
13.Infecciones asociadas a una prótesis permanente que no se va a retirar en las 24 horas siguientes a la inclusión.
14.Shock o hipotensión (presión arterial sistólica en decúbito supino < 80 mm Hg) resistente al tratamiento con líquidos o con un ciclo corto de vasopresores (>4 horas).
15.Recuento de neutrófilos < 1.000/µl.
16.Sospecha o certeza de infección por el VIH con recuento de linfocitos T CD4+ < 500/microlitros; (no es necesario realizar la prueba del VIH).
17.Insuficiencia hepática grave (clase C de Child-Pugh) o elevación de la ALT y/o la AST >5 veces el LSN y/o de la bilirrubina total >2 veces el LSN en la selección.
18.Aclaramiento de creatinina calculado con la ecuación de Cockcroft-Gault (utilizando el peso corporal real) < 30 ml/min o cualquier tipo de diálisis.
19.Esperanza de vida inferior a seis meses.
20.Tratamiento con cualquier fármaco o dispositivo experimental en los 30 días previos a la administración del fármaco del estudio.
21.Pacientes que no quieren o no pueden cumplir los procedimientos y restricciones previstas en el estudio.
22.Pacientes que ingresan en el hospital por abuso de drogas u otros trastornos que se asocian a rabdomiólisis.
Criterios de exclusión relacionados con la microbiología
23.Pacientes con infección debida a un microorganismo resistente a la daptomicina o la vancomicina a la entrada en el estudio.
24.Sospecha o demostración de IPTBc que se debe exclusivamente a microorganismos gramnegativos o anaerobios, basándose en la epidemiología o en la exploración directa de una muestra con tinción de Gram.
Criterios de exclusión relacionados con los medicamentos
25.	Necesidad (a la entrada en el estudio) de un antibiótico sistémico ajeno al estudio (para una infección concomitante), al que el microbio patógeno de interés es sensible.
26.Administración previa de un antibiótico sistémico para el tratamiento de IPTBc por grampositivos durante más de 24 horas en las 48 horas anteriores al día de la primera infusión del fármaco del estudio, a menos que:
el microbio patógeno grampositivo infeccioso tenga una resistencia intermedia o plena in vitro al antibiótico utilizado anteriormente; o
el tratamiento antibiótico anterior se haya administrado durante 3 o más días naturales con empeoramiento o sin mejoría de los signos y síntomas clínicos de las IPTBc, y no se trata de vancomicina ni de una PSS.
27.Administración de un antibiótico sistémico activo in vitro contra cocos grampositivos durante más de 24 horas en las 48 horas previas a la primera infusión de la medicación del estudio, como tratamiento para otro foco de infección o como prevención quirúrgica, a menos que la IPTBc haya aparecido durante este tratamiento.
El investigador no aplicará ningún otro criterio de exclusión para garantizar que la población del ensayo sea representativa de todos los pacientes elegibles.
E.5 End points
E.5.1 Primary end point(s): La variable principal relacionada con el objetivo principal es el resultado clínico (es decir, curación clínica, mejoría, fracaso o no se puede evaluar) en la visita de comprobación de la curación.
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: No
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: Information not present in EudraCT
E.7.1.2 Bioequivalence study: Information not present in EudraCT
E.7.1.3 Other: Information not present in EudraCT
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): No
E.7.3 Therapeutic confirmatory (Phase III): Yes
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: Yes
E.8.1.3 Single blind: No
E.8.1.4 Double blind: No
E.8.1.5 Parallel group: Yes
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): Yes
E.8.2.2 Placebo: No
E.8.2.3 Other: No
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.4.1 Number of sites anticipated in Member State concerned: 5
E.8.5 The trial involves multiple Member States: Yes
E.8.5.1 Number of sites anticipated in the EEA: 22
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: Yes
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned:
E.8.7 Trial has a data monitoring committee: No
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: 
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 1
E.8.9.1 In the Member State concerned months: 6
E.8.9.1 In the Member State concerned days: 0
E.8.9.2 In all countries concerned by the trial years: 1
E.8.9.2 In all countries concerned by the trial months: 6
E.8.9.2 In all countries concerned by the trial days: 0

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Information not present in EudraCT
F.1.2 Adults (18-64 years): No
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Yes
F.3.3.1 Women of childbearing potential not using contraception : No
F.3.3.2 Women of child-bearing potential using contraception: No
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: Yes
F.3.3.6.1 Details of subjects incapable of giving consent: En el caso que el paciente sea incapaz de dar su consentimiento, el representante legal autorizado puede darlo siguiendo los medios aprobados por el CE del investigador
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 18
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 81
F.4.2.2 In the whole clinical trial: 146

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2010-02-22
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2010-02-17

P. End of Trial
P. End of Trial Status: Completed
P. Date of the global end of the trial: 2011-03-24

